Alzheimer’s Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?
The amyloid cascade hypothesis for Alzheimer’s disease is still alive, although heavily challenged. Effective anti-amyloid immunotherapy would confirm the hypothesis’ claim that the protein amyloid-beta is the cause of the disease. Two antibodies, aducanumab and lecanemab, have b...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Published: |
MDPI AG
2024
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/1721.1/154127 |